Drug stewardship for RAS-inhibitors and SGLT2-inhibitors in chronic kidney disease: stay on, restart

Renin-angiotensin system (RASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are the cornerstones of management for patients with chronic kidney disease (CKD). The use of these treatments is limited by frequent discontinuations, increasing the risk of death and compromising cardiovascular and renal health. This narrative review explores scenarios that lead to discontinuation: adverse effects (i.e. RASi-related acute kidney injury and …